New Components Including Cyclopeptides from Barks of Christiana africana DC. (Tiliaceae)

by Serge Michalet^a), Laëtitia Payen-Fattaccioli^a), Chantal Beney^a), Pascale Cégiéla^a), Christine Bayet^b), Gilbert Cartier^a), Diderot Noungoué-Tchamo^c), Etienne Tsamo^c), Anne-Marie Mariotte^a), Marie-Geneviève Dijoux-Franca^{*a})¹)

^a) Laboratoire de Pharmacognosie, Département de Pharmacochimie Moléculaire, UMR 5063 CNRS-UJF, UFR de Pharmacie de Grenoble I, Domaine de la Merci, F-38706 La Tronche cedex (phone: $+33$ (0)478777052; fax: $+33$ (0)478777565; e-mail: dijoux@sante.univ-lyon1.fr) b) Université de Lyon, UMR CNRS 5557-Ecologie Microbienne, ISPB, 8 avenue Rockefeller, F-69373 Lyon cedex 08

c) Laboratory of Organic Chemistry, Faculty of Sciences, University of Yaoundé I, Yaoundé, Cameroon

Phytochemical investigation of barks of Christiana africana led to the identification of cyclopeptide alkaloids, flavonoids, coumarinolignans, iridoids, sesquiterpenoids, and triterpenes. This plant was classified so far in the Tiliaceae family. This study was started while the genomic study of numerous specimens was described in order to establish new criteria for Malvales botanical classification. In the present work, twenty components were identified, belonging to the three major classes of secondary metabolites: alkaloids, phenols, and terpenes. In the first class, cyclopeptides are well-known compounds in Rhamnaceae and Sterculiaceae. Their presence in Malvaceae (in APG2 sensus) suggests a possible chemical link between the ex-Tiliaceae and the Malvaceae.

Introduction. – Christiana africana DC. is a tropical tree well-known in Cameroon for its use in folk medicine for hypertension treatment. It was classified by Hutchinson [1], Cronquist [2], and Judd and Manchester [3] in Malvales order, and Tiliaceae family. To establish new criteria for Malvales botanical classification, two genomic studies of numerous specimens were described in 1999 [4] [5]. Eleven families were studied including the Malvaceae. According to the genomic profile, most of the Tiliaceae could join this family, while Tilioidae (ex-Tiliaceae) were composed of the genus Tilia and Craigia. Thus in the APG2 classification, the Malvaceae included ten sub-families, among them the Sterculioideae (ex-Sterculiaceae) and the Brownlowioidae. C. africana belongs to the latter, together with eight other genuses [6]. But until now, no chemical study had been published on Christiana sp.

In our course in studying the chemistry of natural products and to better understand biodiversity of the plant kingdom, it seemed valuable to investigate the chemical composition of this species in order to access new bioactive compounds, but also to see if the chemical profile presents a good phenotype expression regarding the APG2 classification.

© 2008 Verlag Helvetica Chimica Acta AG, Zürich

¹) New address: UMR CNRS 5557, Univ. de Lyon (Lyon 1, Claude Bernard), ISPB, Dépt. Botanique et Pharmacognosie, 8 Av. Rockefeller, F-69373 Lyon cedex 08.

Results and Discussion. – This report deals with the isolation and identification of cyclopeptide alkaloids (frangulanin and melonovin), phenylpropanoid (aviculin), coumarinolignan (cleomiscosin A), iridoids (loganin, deoxyloganin, geniposide, dihydrogeniposide), chromone, sesquiterpenoids, and triterpenes from the barks of C. africana. Cyclopeptide alkaloids could be surprising in Tiliaceae, but not in Malvaceae. Indeed, in the same order (Malvales), the Rhamnaceae are well-known for containing these phytoconstituents. Thus, their presence would be discussed in term of interest as a first chemical link in the new classification.

From different crude extracts, the purified compounds were identified on the basis of their spectroscopic data and comparison with the literature. Together with the known components, five new compounds were also identified: three sesquiterpenoids, a chromone, and a triterpene. Two different procedures were realized in order to obtain $a)$ crude extracts of increasing polarity and $b)$ a crude alkaloid extract.

1. Structure Elucidation. From the hexane extract, the four triterpenes and two sterols were identified as taraxerol (1) [7] [8], lupeol, α - and β -amyrin [9], β -sitosterol, and stigmasterol [10], respectively.

From the MeOH extract, nine compounds were identified as two cyclopeptide alkaloids (frangulanin (2) [11] [12] and melonovin (3) [13]), four iridoids (loganin [14], geniposide [15], dihydrogeniposide [16] [17], deoxyloganin (4) [18]), three phenolic derivatives (scopoletol [10] [19], aviculin (5) [20], and cleomiscosin A (6) $[21-23]$).

From the CH₂Cl₂/MeOH (1:1) extract, six of these known compounds were also identified (frangulanin (2) [11] [12], melonovin (3) [13], and $4-6$), together with three new sesquiterpenoids $(i.e., 7-9)$ and a new triterpene 10.

Analysis of the EI-MS of 7 revealed a pseudo-molecular ion at m/z 232 (M^+) corresponding to the molecular formula $C_{15}H_{20}O_2$. ¹H- and ¹³C-NMR spectra showed signals for four Me, two $CH₂$, and four CH groups, as well as five quaternary C-atoms (see Table 1). The ${}^{1}H, {}^{1}H$ -COSY exhibited two spin systems with, on one hand, two Me groups at $\delta(H)$ 1.70 (d, $J = 6.8$, H – C(13)) and 1.15 (d, $J = 7.2$, H – C(12)), and a CH₂ group at 3.00 (br. *hept*, $J = 6.9$, $H - C(11)$), which indicated an ⁱPr group. The second spin system included nine H-atoms. A CH₂ group at $\delta(H)$ 2.68 (dd, $J = 6.8$, 18.0, $H-C(2)/2.26$ (dd, $J = 2.0, 18.0, H-C(2')$) was coupled to a CH group at 2.57 – 2.63 (m, $H-C(1)$, which showed a cross-peak with $H-C(10)$ at 1.82 – 1.85 (*m*). $H-C(10)$ was correlated with a Me group at 1.19 $(d, J = 6.4, H - C(15))$ and a CH₂ group at 2.93 (dd, $J = 4.8, 12.0, H-C(9)/2.44$ (*dd, J* = 4.0, 12.0, H-C(9')). Finally, long-range couplings were observed between an olefinic H-atom (6.89, br. s, $H-C(6)$) and $H-C(11)$ on one side, and a Me group at 1.88 (d, $J = 1.6$, Me(14)), on the other side. The ¹³C-NMR spectrum showed 15 C-atoms, thereof two CO groups at $\delta(C)$ 204.3 (C(8))/208.0 $(C(3))$, three quaternary C-atoms at 164.0 $(C(5))$ /155.3 $(C(7))$ /139.5 $(C(4))$, four CH groups at 126.7 (C(6))/47.3 (C(1))/36.6 (C(10))/31.4 (C(11)), two CH₂ groups at 41.9 $(C(2))/51.6 (C(9))$, and four Me groups at 8.62 $(C(14))/22.1 (C(15))/21.5 (C(13))/21.3$ $(C(12))$. Examination of the results of the ${}^{1}H, {}^{1}H$ -COSY, HMQC and HMBC experiments (see Table 1 and Fig.) allowed the identification of two substructures: $O=C-C(Me)=C-CH=C('Pr)-C=O$, and $O=C-CH_2-CH-CH(Me)-CH_2-$ C=O. As $H-C(2/2')$ showed cross-peaks with $C(5)/C(3)/C(1)$, $H-C(9/9')/H-C(6)$ with $C(8)/C(1)$, and finally $H-C(14)$ with $C(5)/C(3)$, i) $C(5)$ was connected to $C(1)$, and $ii) C(3)$ and $C(8)$ were common to both substructures. Altogether, these data were

used to identify 7 as 3,3a,4,5-tetrahydro-1,4-dimethyl-7-(1-methylethyl)azulene-2,6 dione or $(1\beta,10\alpha H)$ -guaia-4,6-dien-3,8-dione. The relative configuration of C(1) and $C(10)$ was established by means of the coupling constants between $H-C(2)/H-C(2')/T$ $H-C(1)/H-C(10)$, together with NOESY data. The NOESY experiment exhibited NOE effects between $H-C(15)$ and $H-C(1)/H-C(9')/H-C(2')$, which showed that they are placed on the same side of the molecule. This deduction was supported by the large coupling constants $J(1,2)$ (6.8 Hz) and $J(1,10)$ (9.6 Hz), suggesting that H-C(1) and $H-C(10)$ are *trans* to each other [24]. NOE cross-peaks were also observed

| | 7 | | 8 | | 9 | |
|--------------|-------------------------------------|-------------|-------------------------------------|-----------------------------|--|-------------|
| | $\delta(H)$ | $\delta(C)$ | $\delta(H)^a$ | $\delta(C)^a$) $\delta(H)$ | | $\delta(C)$ |
| 1 | $2.57 - 2.63$ (<i>m</i>) | 47.3 | $2.50 - 2.60$ (<i>m</i>) | 49.0 | $2.58 - 2.72$ (<i>m</i>) | 47.0 |
| 2 | 2.68 (dd, $J=6.8$, 18.0) | 41.9 | 2.65 (dd, $J = 6.0, 18.4$) | 41.4 | 2.57 (dd, $J = 6.5$, 18.0) | 42.5 |
| 2^{\prime} | 2.26 (dd, $J = 2.0, 18.0$) | | 2.19 (dd, $J = 2.4$, 18.4) | | 2.12 $(dd, J=1.4, 17.8)$ | |
| 3 | | 208.0 | $\qquad \qquad -$ | 204.5 | | 206.4 |
| 4 | | 139.5 | $\overline{}$ | 135.7 | | 135.9 |
| 5 | | 164.0 | | 169.6 | | 168.3 |
| 6 | 6.89 (br. s) | 126.7 | 6.38 (br. s) | 118.4 | 6.40 (br. s) | 123.0 |
| 7 | | 155.3 | | 161.9 | | 157.8 |
| 8 | | 204.3 | 4.50 (dd, $J = 1.2, 7.6$) | 67.9 | 2.19 $(dd, J=8.5, 17.0)^{b}$ | 26.5 |
| 8' | | | | | 2.45 $(dd, J=7.4, 17.5)^{b}$ | |
| 9 | 2.93 (dd, $J = 4.8$, 12.0) | 51.6 | 2.10 (ddd, $J = 4.0, 7.6, 14.0$) | 44.3 | $1.80 - 1.90$ (<i>m</i>) | |
| 9^{\prime} | 2.44 $(dd, J=4.0, 12.0)$ | | 1.75 (ddd, $J = 1.6, 8.4, 14.0$) | | $1.50 - 1.70$ (<i>m</i>) | 35.6 |
| 10 | $1.82 - 1.85$ (<i>m</i>) | 36.6 | $1.88 - 1.92$ (<i>m</i>) | 33.3 | $1.50 - 1.70$ (<i>m</i>) | 39.2 |
| 11 | 3.00 (br. <i>hept</i> , $J = 6.9$) | 31.4 | 2.77 (br. <i>hept</i> , $J = 6.8$) | 34.7 | $2.58 - 2.72$ (<i>m</i>) | 47.4 |
| 12 | 1.15, $(d, J = 7.2)$ | 21.3 | 1.16 $(d, J=6.8)$ | 21.2 | $3.59 - 3.70$ (<i>m</i>)/ | 66.1 |
| | | | | | 3.21 (dd, $J=6.1$, $10.5)^{b}$) | |
| $12' -$ | | | | | $3.59 - 3.70$ (<i>m</i>)/ | |
| | | | | | 3.29 (dd, $J = 7.8$, 10.7) ^b) | |
| 13 | 1.70 $(d, J=6.8)$ | 21.5 | 1.19 $(d, J=6.8)$ | 21.3 | 1.08 $(d, J=6.6)$ | 16.0 |
| 14 | 1.88 $(d, J=1.6)$ | | 8.62 1.72 $(d, J=1.6)$ | 6.7 | 1.77 (br. s) | 8.6 |
| 15 | 1.19 $(d, J=6.4)$ | 22.1 | 1.12 $(d, J=6.4)$ | 20.9 | 1.04 $(d, J=6.5)$ | 22.3 |

Table 1. ^{*IH*}- and ¹³C-NMR Data of **7–9**. At 400/100 MHz, resp., in CDCl₃; δ in ppm, J in Hz.

^a) Data in CDCl₃ plus three drops of CD₃OD. ^b) Data in (D_5) pyridine.

Figure. HMBC Correlations of 7 – 9

between $H-C(6)$ and $H-C(13)/H-C(14)$, confirming that these groups were on the same side of the molecule.

The ¹H-NMR spectrum of 8 was compared to that of 7. A double *doublet* was observed at δ 4.50 ($J = 1.2, 7.6, 1$ H, H $-C(8)$). In the COSY spectrum, cross-peaks of H-C(8) with two H-atoms of a CH₂ group at 2.10 and 1.75 (ddd, $J = 4.0, 7.6, 14.0,$ H-C(9) and ddd, $J = 1.6$, 8.4, 14.0, H-C(9'), resp.) were observed. The signal of $H-C(9)$ showed a long-range coupling with the signal of $H-C(1)$ (2.50 – 2.60, *m*), and the latter was coupled with the signal of $H-C(10)$ (1.88 – 1.92, m), which correlated with the signal of Me(15) (1.12, $d, J = 6.4$). The signal of H – C(1) exhibited other crosspeaks with the signals of a CH₂ group at 2.65 (dd, $J = 6.0, 18.4, H-C(2)$) and 2.19 (dd, $J = 2.4, 18.4, H - C(2')$). Beside these signals, the spectra exhibited two Me groups as *doublets* at 1.19 and 1.16 ($J = 6.8$, Me(13) and Me(12)). They both belong to an ⁱPr group, as they showed a cross-peak with a methine at 2.77 (br. hept, $J = 6.8$, H $-C(11)$). HMQC and HMBC experiments allowed the assignment of all 15 C-atoms of the molecule (see Table 1 and Fig.). The FAB-MS data confirmed the molecular weight with a pseudo-molecular ion peak at m/z 235 (C₁₅H₂₃O₂, [M + H]⁺). Altogether, 8 was identified as the new guaiane-type sesquiterpene 6,7,8,8a-tetrahydro-6-hydroxy-5-(1 methylethyl)-3,8-dimethyl-1H-azulen-2-one or $(1\beta, 8\beta, 10\alpha H)$ -8-hydroxyguaia-4,6-dien-3-one. The relative configuration was deduced from the coupling constants and NOESY data. The coupling constant $J(8,9) = 7.6$ Hz suggested that H-C(8) and H-C(9) are trans to each other [24]. The coupling constants $J(1,2)$ of 6.0 and $J(1,2')$ of 2.4 Hz, suggested that $H-C(1)$ and $H-C(2)$ were eclipsed on the same side of the fivemembered ring, while $H-C(2')$ was on the opposite side [24]. Nuclear *Overhauser* effects were noticed through cross-peaks between $H-C(6)$ and $H-C(14)/H-C(11)/$ $H-C(12)$, between $H-C(8)$ and $H-C(11)/H-C(15)/H-C(1)$, between $H-C(15)$ and $H-C(2')/H-C(9)$, confirming the relative configuration at $C(8)$, $C(10)$, and $C(1)$.

Compound 9 was closely related to 7 and 8. The positive FAB-MS exhibited a pseudomolecular ion at m/z 257 ($[M + Na]^+$) and 235 ($[M + H]^+$), corresponding to the same molecular formula as 8. Fragmentation of this ion gave a peak at m/z 207 $([M - CO]^+)$, indicative of the loss of a CO or an ethylene subunit. The ¹H-NMR spectrum exhibited peaks between δ 1.00 and 6.40, with 2 Me *doublets* ($J = 6.5$ and 6.6) at 1.04 and 1.08. Beside these signals, aliphatic H-atoms were observed between 1.61 and 2.60, and a *multiplet* at 3.62 $(2 H)$, which were assigned through the $^1H,^1H$ -COSY correlations. The spectrum of the same compound in $(D₅)$ pyridine exhibited some differences: the *multiplet* at 3.62 was changed into two double *doublets* at 3.29 ($J = 10.7$, 7.8, $H-C(12)$) and 3.21 ($J = 10.5, 6.1, H-C(12')$) (Table 1). Cross-peaks in the HMOC spectrum allowed to assign these H-atoms to a CH₂OH group (δ (C) 66.1, C(12)). The COSY experiment and the ¹ H-NMR shifts showed two spin systems, identifying the following substructures: $RO-CH_2-CH(Me)-C=$, and $= C-CH_2-CH_2-CH(Me)-C₁$ CH-CH₂-C=. The ¹³C-NMR spectra analysis led to four C=C C-atoms (168.3 (s), 157.8 (s) , 135.9 (s) , 123.0 (d) , three aliphatic CH (47.4, 47.0, 39.2), four CH₂ (66.1, 42.5, 35.6, 26.5) and three Me (22.3, 16.0, 8.6) groups. The HMBC correlations were used to establish the connectivities between these substructures (Fig.). Comparing these data to those of 7 and 8, 9 was identified as 6,7,8,8a-tetrahydro-5-(2-hydroxy-1-methylethyl)-3,8-dimethyl-1H-azulen-2-one or $(1\beta,10\alpha H)$ -12-hydroxyguaia-4,6-dien-3-one, a third guaiane-type sesquiterpene. As before, the relative configuration at C(1) and C(10) was established by means of the size of the coupling constants and NOESY data. NOESY Correlations observed between $H-C(6)$ and Me(14)/Me(13), and between $H-C(1)$ and Me(15) suggested that $H-C(6)$, Me(14), and Me(13) were co-planar and that $H-C(1)$ and $Me(15)$ were on the same side of the molecule (*Fig.*).

The ¹H-NMR spectrum of 10 exhibited signals between δ 5.43 and 0.90, suggesting a triterpenic structure [7]. Eight Me group *singlets* at 1.51 (Me(24)), 1.42 (Me(23)), 1.26 $(Me(26)), 1.23(Me(27)), 1.12(Me(25)), 1.01(Me(28)), 1.00(Me(29)), 0.90(Me(30)),$ four CH groups at 5.43 (br. $d, J = 3.2, H - C(12)$), 3.87 (br. $d, J = 7.6, H - C(1)$), 3.35 (d, $J = 10$, H – C(21)) and 3.28 (d, $J = 10$, H – C(22)), and numerous signals between 3.32 and 1.81 ppm were indicative of a polyoxygenated triterpene. The 13C-NMR signals were in accordance with this hypothesis: 30 C-atoms were detected between δ 171.8 and 14.5 (Table 2), including eight Me, six $CH₂$, and seven CH groups, as well as nine quaternary C-atoms. The presence of a $C = C$ bond and the oxygenated positions were confirmed as follows: 142.9 (C(13))/124.2 (C(12)), and the C-atoms at 215.1 (C(7))/ 171.8 (C(3))/84.5 (C(4))/79.9 (C(22))/77.5 (C(21))/69.1 (C(1)). A ¹H,¹H-COSY experiment allowed the identification of six spin systems. Thus, $C(21)$ and $C(22)$, and $C(1)$ and $C(2)$ were deduced to be vicinal C-atoms. Cross-peaks between $H-C(12)$ ($\delta(H)$) 5.43) and the CH₂ group H-C(11) (2.00 – 2.06)/H-C(11') (2.12 – 2.17) pointed to the substructure $-C=CH-CH_2-C$. A HMQC experiment allowed the assignment of Hsubstituted C-atoms. Combined ¹H,¹H-COSY, HSQC, and HMBC data were used to elucidate the structure of 10 as a new metabolite, a homo-3a-oxa-1,21,22-trihydroxyolean-12-ene-3,6-dione (Table 2).

A NOESY experiment was helpful for the determination of the relative configuration (Table 2). D/CI-MS spectra exhibited a pseudo-molecular ion at m/z 503 assigned to $[M + H]$ ⁺. Fission of ring C led to two main ions with m/z 253 (99.7%) and 251 (47.9%). These data were in accordance with the molecular formula $C_{30}H_{46}O_6$. From these data, two structures were proposed for the ring \vec{A} (10a and 10b). A definitive choice was made based on the chemical shifts of $C(1)$, $C(2)$, $C(3)$, and $C(4)$. According to the literature, a C=O C-atom in a lactone as in the structure of $10a$ exhibited an upfield shift at $\delta(C)$ 175.6, while the tertiary carbinol C-atom (C(4)) was shifted downfield at δ (C) 85.6 [25]. In the seco-ring form (10c) the COOH group was observed at $\delta(C)$ 180.6 and the carbinol C-atom at $\delta(C)$ 75.9. The same conclusion was deduced from data of limonoids, which presented the same ring A as 10 [26]. The shape of ring A in 10b was observed also in the limonoid class [27]. In this case, $C(1)$ to $C(4)$ were detected at δ (C) 81.6, 36.9, 172.1 and 78.1, respectively. From this analysis, the structure 10a is proposed for the structure of this novel metabolite 10.

From the basic crude extract, the major compounds were identified by means of their spectral data as the cyclodipeptides frangulanin (2) [11] [12] and melonovin (3) [13]. Beside these cyclopeptides, another compound was isolated. The EI-MS of 11 exhibited an ion peak at m/z 261 (97, $[M - Me]^+$) and fragments at m/z 232 (76, $[M -$ 44]⁺), 218 (20, $[M-58]$ ⁺), 205 (100, $[M-71]$ ⁺), and 177 (15, $[M-99]$ ⁺). The base peak most likely arises from benzylic cleavage of an aliphatic C_6 chain. Positive FAB-MS analysis showed the molecular ion at m/z 277 ($[M + H]^+$), which was consistent with the formula C₁₆H₂₀O₄. The UV spectrum in MeOH showed five bands at λ 334, $321, 292$ (sh), 244 , and 216 nm. With $AlCl₃$, a bathochromic effect was observed on bands 1 and 2. This effect was permanent after addition of HCl (25%). This suggested the presence of a γ -hydroxyketone group. The ¹H-NMR spectrum of 11 was closely related to that of the 5-hydroxy-7-methoxy-2-pentyl-4-chromone described by Jimenèz *et al.* [28]. At $\delta(H)$ 6.40 (H–C(6)) and 6.34 (H–C(8)), two *doublets* ($J = 2.3 \text{ Hz}$) suggested two aromatic H-atoms in *meta*-position to each other. At 6.19, a *singlet* was assigned to $H-C(3)$. A MeO group was observed at 3.83 (s). Additionally, the aliphatic H-atoms showed the following signals: a *triplet* at 2.48 ($J = 7.7$, CH₂(1')), two multiplets between 1.30 and 1.70 (CH₂(2') to CH₂(5')), and a triplet at 0.89 ($J = 7.1$, $Me(6')$). These signals, together with the MS data, were consistent with the presence of an n-hexyl group. A broad singlet was observed at 12.43, and was assigned to $HO-C(5)$. The ¹³C-NMR spectrum exhibited 15 C-atoms with two Me (δ (C) 13.9 and

| | 10 | | | $10a^a)$ | $10a^b)$ | $10b^c$ | $10ca$) |
|-----------------|---|--------------|-------------|-------------|-------------|-------------|-------------|
| | $\delta(H)$ | NOESY | $\delta(C)$ | $\delta(C)$ | $\delta(C)$ | $\delta(C)$ | $\delta(C)$ |
| $\mathbf{1}$ | 3.87 (br. $d, J = 7.6$) | 2, 9, 11, 25 | 69.1 | | 70.0 | 81.6 | |
| 2a | 3.01 (dd, $J = 7.6$, 16.0) | 25 | 39.8 | | 40.1 | 36.9 | |
| 2 _b | 3.32 $(d, J=15.6)$ | | | | | | |
| 3 | $\overline{}$ | | 171.8 | 175.6 | 174.3 | 172.1 | 180.6 |
| $\overline{4}$ | | | 84.5 | 85.6 | 86.3 | 78.1 | 75.9 |
| 5 | 2.67 (dd, $J=6.0, 13.2$) | 24, 9, 27 | 46.5 | | | | |
| 6a | 2.55 (dd, $J = 6.0, 18.3$) | 24 | 42.1 | | | | |
| 6b | $2.32 - 2.40$ (<i>m</i>) | 23, 25 | | | | | |
| 7 | $\overline{}$ | | 215.1 | | | | |
| 8 | | | 45.6 | | | | |
| 9 | 2.87 $(dd, J=4.1, 12.0)$ | 5, 27 | 41.7 | | | | |
| 10 | $\overline{}$ | | 44.2 | | | | |
| 11a | $2.12 - 2.17(m)$ | $\mathbf{1}$ | 23.7 | | | | |
| 11 _b | $2.00 - 2.06$ (<i>m</i>) | $\mathbf{1}$ | | | | | |
| 12 | 5.43 (br. $d, J = 3.2$) | 18 | 124.2 | | | | |
| 13 | $\overline{}$ | | 142.9 | | | | |
| 14 | | | 55.0 | | | | |
| 15a | $1.93 - 2.00$ (m) | 27 | 27.3 | | | | |
| 15 _b | $1.60 - 1.65$ (<i>m</i>) | 26, 28 | | | | | |
| 16a | $1.65 - 1.72$ (<i>m</i>) | | 21.2 | | | | |
| 16 _b | $1.49 - 1.56$ (<i>m</i>) | | | | | | |
| 17 | | | 39.9 | | | | |
| 18 | $2.06 - 2.12$ (<i>m</i>) | 21, 28, 30 | 48.8 | | | | |
| 19a | 1.81 $(t, J=13.6)$ | | 44.8 | | | | |
| 19 _b | $1.20 - 1.25$ (<i>m</i>) | | | | | | |
| 20 | $\overline{}$ | | 36.1 | | | | |
| 21 | 3.35 $(d, J = 10.0)$ | 18, 28, 30 | 77.5 | | | | |
| 22 | 3.28 $(d, J = 10.0)$ | 19, 16, 29 | 79.9 | | | | |
| 23 _b | 1.42 (s) | 2, 6 | 22.6 | | | | |
| 24a | 1.51(s) | 5,6 | 33.6 | | | | |
| 25 _b | 1.12(s) | 1, 6, 11 | 15.6 | | | | |
| 26 _b | 1.26(s) | 15 | 17.6 | | | | |
| 27a | 1.23(s) | 5, 6, 9, 15 | 27.4 | | | | |
| 28 _b | 1.01(s) | 15, 18, 21 | 25.4 | | | | |
| 29a | 1.00(s) | 19, 22 | 14.5 | | | | |
| 30 _b | 0.90(s) | 18, 21, 22 | 30.0 | | | | |
| | a) From [25]. b) From [26]. c) From [27]. | | | | | | |

Table 2. ^{*IH*}- and ¹³C-NMR Data of **10–10c**. At 400/100 MHz, resp., in CDCl₃; δ in ppm, *J* in Hz.

55.4), five CH₂ (22.3 – 33.3), and three CH (105.3, 99.5 and 99.3) groups, as well as six quaternary C-atoms (179.2, 166.3, 165.1, 157.2, 140.8, and 114.5). As observed in the ¹H-NMR spectrum, the ¹³C-NMR shifts were closely related to the pertinent reference value [28]. Thus, the spectral data suggested a flavone type of structure, namely 5 hydroxy-2-hexyl-7-methoxy-4-chromone. As quinolones were identified in Sterculiaceae [29], and to insure that 11 was not an alkaloid, the quinolone 11a was synthesized starting from 3,5-dimethoxyaniline and hexanoyl chloride, using a method described by

Scheme. Synthesis of 11a

Hadjeri et al. [30] (Scheme). Spectroscopic data of 11a showed that it was different from our natural product 11.

2. Interest of the Metabolites in the APG2 Classification. Compounds 7-9 were identified for the first time in the plant kingdom. Up to now, the guaiane-type sesquiterpenoids were essentially found in Asteraceae [31], and occasionally in Apiaceae, Thymeleaceae, Valerianaceae, Zingibearaceae, Rutaceae, in liverworts and in marine sponges $[32-38]$. Dimers were also identified in Xylopia vielana (Annonaceae) $[39-41]$. But this is so far the first report of guaianes in Malvaceae.

Seco-triterpenes have been reported from unrelated families without any botanical link: Celastraceae, Meliaceae, Apiaceae, Saxifragaceae [42 – 45]. Only few biological activities have been detected in these compounds.

Finally, beside the identification of new compounds, the surprising feature in this work is the identification of cyclopeptides. It is a newly reported approach to consider these compounds as potential chemotaxonomic markers. This interest arose with the recent APG2 classification. Indeed, in 2003, C. africana (together with the Brownlowioideae sub-family) was reclassified as belonging to the Malvaceae, instead of Tiliaceae. It is the second time that these compounds are reported in this family (in APG2 sensus): Emile et al. found frangulanin (2) in Melochia odorata [46]. Furthermore, the 14-membered dipeptides are reported to be present in 7 out of 27 (26%) core eudicot orders [47]. As the APG2 classification is based on genomic criteria, cyclopeptides can be looked upon as the first phenotype expression of the APG and the very first chemical link between C. africana and other species already known for containing this class of metabolites and belonging to Rosid plants.

This work was supported by the Pierre Fabre Institute. The authors are thankful to Dr. B. David and Dr. A. Cassan for their interest and Prof. E. Tsamo for the plant sample identification.

Experimental Part

General. Column chromatography (CC) was performed on silica gel (SiO₂) 60 (40–63 μ m; Merck), on Sephadex LH-20 gel (Amersham Pharmacia, Sweden), or on polyamide (NN-Polyamid-SC6, < 0.07 mm; Macherey-Nagel). Vacuum Liquid Chromatography (VLC) was performed on SiO₂ (40 – 63 µm, Merck). Solid Phase Extraction (SPE) was performed on C_{18} reverse phase: Lichroprep 60 $RP-18$ (40-63 µm, Merck). TLC: SiO₂ 60 F_{254s} (Merck). Prep. TLC: SiO₂ 60 GF_{254s} (Merck). UV Spectra: Hitachi U2000 spectrophotometer; λ_{max} in nm. Optical rotations: Perkin-Elmer 241 polarimeter, at 20°. NMR Spectra: *Bruker AC* spectrometer, at 200/400 (1 H) and 50/100 MHz (13 C) resp.; chemical shift δ in ppm, coupling constant J in Hz. 1H , 1H -COSY, HSQC, HMBC, and NOESY Spectra: *Bruker* DRX-500 spectrometer. EI-MS, D/CI-MS and FAB-MS: R210C quadripolar spectrometer. HR-ESI-MS: Thermo-Finnigan Mat 95 XL ; in m/z .

Plant Material. Barks of C. africana were collected in 1996, in the region of Ngoumé $(5^{\circ}30' N, 11^{\circ}22'$ E, Cameroon). A voucher specimen has been deposited with our laboratory (N° 1995R1).

Extraction and Isolation. The dried barks of C. africana (2.77 kg) were successively extracted with four solvents of increasing polarity, to give cyclohexane $(23.5 g)$, CH₂Cl₂ (20.0 g), CH₂Cl₂/MeOH (68.0 g) , and MeOH (422.3 g) extracts.

The CH₂Cl₂/MeOH (1:1) crude extract (25 g) was treated with NaCl. After filtration, the aq. phase was partitioned against CH₂Cl₂, AcOEt, and BuOH to give the three extracts F1 (262 mg), F2 (886 mg) and F_3 (2.72 g). F1 was subjected to purification on VLC using SiO₂ as stationary phase and a gradient of CH₂Cl₂/MeOH as mobile phase. Nine fractions were obtained ($F1a-F1i$). F1b (15 mg) gave 7 (3.2 mg) and scopoletol [10] [19] (1 mg) after separation by CC on SiO₂ with a step gradient of CH₂Cl₂/MeOH/ $NH₄OH$ (98:2:1, 130 ml), (95:5:1, 50 ml) and then MeOH (25 ml). Compound 7 and scopoletol $[10][19]$ were eluted in the first and the second step, resp. F1d (72 mg) was submitted subsequently to a filtration over Sephadex LH-20 in MeOH/H₂O (9:1) and SPE over C_{18} using a gradient of H₂O/MeOH $(100:0 \rightarrow 0:100)$, to yield 9 (3.9 mg), 4 (4 mg), and 6 (3 mg). *F1e* (58 mg) was purified by CC over SiO₂ using a mixture of CH₂Cl₂/MeOH/NH₄OH (97:3:1) to give 7 fractions. The first one (7 mg) yielded frangulanin (2) [11] [12] (2 mg) after additional CC over $SiO₂$ with $CH₂Cl₂/MeOH/NH₄OH (98:2:1)$. The fifth fraction (11 mg) yielded 10 (1.3 mg), after being purified by SPE over C_{18} using a gradient of $H_2O/MeOH$ (90:10 \rightarrow 0:100).

F 2 (886 mg) was subjected to VLC over C_{18} using a gradient of H₂O/MeOH (100 : 0 \rightarrow 0 : 100) to give 17 fractions ($F2a-F2o$). F2l (177 mg) was submitted to CC on polyamide using a gradient of H₂O/ MeOH (100 : $0 \rightarrow 60$: 40) to give 8 fractions. The fourth fraction yielded 5 (2 mg) after purification by CC over $SiO₂$ using a mixture of AcOEt/MeOH/H₂O (100:16.5:13.5).

After the removal of the tannins [48], and evaporation under vacuum, the MeOH extract $(2 g)$ was dissolved in H_2O , and partitioned with CH₂Cl₂, to give 300 mg of an org. residue. The latter was purified by CC on SiO₂ using a gradient of cyclohexane/CH₂Cl₂ (2 : $8 \rightarrow 0$: 100), and then CH₂Cl₂/MeOH/NH₄OH (10%) $(100:0:0 \rightarrow 95:4:1)$. The fraction eluted with the step gradient of 97:2:1 was further purified by prep. TLC in the same solvent to yield frangulanin (2) [11] [12] (2 mg). Finally, the fraction eluted with $CH_2Cl_2/MeOH/NH_4OH$ (10%) (95:4:1) led to melonovin (3) [13] after prep. TLC under the same conditions.

A second purification of the MeOH extract (28 g) with skin powder and partitioning with CH₂Cl₂ and BuOH led to three extracts. The aq. extract (959 mg) was successively purified by 1) CC over Sephadex LH-20 in MeOH, and 2) SPE over $SiO₂$ with a gradient $CH₂Cl₂/MeOH/H₂O$. The fraction eluted with 80 : 20 : 0 (213 mg) was then purified by SPE over C_{18} using a H₂O/MeOH gradient. The first fraction (9 mg) was further purified by prep. TLC in CH₂Cl₂/MeOH (8:2) and gave loganin [14] (2.5 mg) .

Finally, an alkaloid type extract was prepared from 1 kg of bark, according to a slightly modified procedure originally described by *Ghedira et al.* [49]. After maceration in NH₄OH (10% aq), the powder

was extracted with CH₂Cl₂ (16 l) for 65 h. Partitioning with H₂O and evaporation of the org. phase under reduced pressure led to 7 g of a crude extract. This extract $(7 g)$ was subjected to a *Sephadex LH-20* CC in a mixture of cyclohexane/CH₂Cl₂ (4:6) and led to 21 fractions. Fr. A8 (160 mg) was then subsequently purified by LPLC (using C_{18} and a gradient H₂O/MeOH as solvent), by SPE on SiO₂ (gradient cyclohexane/CH₂Cl₂/MeOH), and finally by prep. TLC on SiO₂ with CH₂Cl₂/MeOH (93:7) as the mobile phase. This yielded 8 (4 mg) and 11 (3 mg). Fr. A21 (443 mg) was purified by HPLC (C_{18} , H₂O/ MeOH 1:1) and then by *Visiprep* on $SiO₂$ with a gradient of cyclohexane/CH₂Cl₂/MeOH.

(4R)-3,3a,4,5-Tetrahydro-1,4-dimethyl-7-(1-methylethyl)azulene-2,6-dione (7). Colorless oil. $[a]_0^{20}$ = -13.5 (c = 0.16), CHCl₃). ¹H- and ¹³C-NMR: *Table 1*. EI-MS: 232 (M^+), 217 ([M – Me]⁺), 190 ([M – $(Me-CH=CH₂)$]⁺). HR-ESI-MS: 255.31535 ([M + Na]⁺, C₁₅H₂₀NaO₂⁺; calc. 255.13610).

(6S,8R)-6,7,8,8a-Tetrahydro-6-hydroxy-3,8-dimethyl-5-(1-methylethyl)-1H-azulen-2-one (8). Colorless oil. $[\alpha]_D^{20} = -21.3$ ($c = 0.2$), CHCl₃). ¹H- and ¹³C-NMR: *Table 1*. FAB-MS (pos.): 257 ($[M + Na]^+$), 235 $([M + H]^+)$, 207 $([M - CO]^+)$. EI-MS: 234 (M^+) . HR-ESI-MS: 257.15195 $([M + Na]^+)$ $C_{15}H_{22}NaO_2^+$; calc. 257.15175).

(8R)-6,7,8,8a-Tetrahydro-5-(2-hydroxy-1-methylethyl)-3,8-dimethyl-1H-azulen-2-one (9). Colorless oil. $\left[\alpha\right]_0^{20} = 93$ (c = 0.2), CHCl₃). ¹H- and ¹³C-NMR: *Table 1*. FAB-MS: 257 ($\left[M + Na\right]$ ⁺), 235 ($\left[M +$ H]⁺). EI-MS: 234 (M⁺). HR-ESI-MS: 257.15190 ([M+Na]⁺, C₁₅H₂₂NaO₂⁺; calc. 257.15175).

(1S,5aR,7aR,7bR,9aR,10S,11S,13aS,15bR)-1,5a,6,7a,7b,8,9,9a,10,11,12,13,13a,15,15a,15b-Hexadecahydro-1,10,11-trihydroxy-5,5,7a,7b,9a,12,12,15b-octamethylchryseno[2,1-c]oxepine-3,7(2H,5H)-dione (10) . Colorless oil. $[\alpha]_D^{20} = 9.2$ ($c = 0.065$, CHCl₃). ¹H- and ¹³C-NMR: *Table 2*. D/CI-MS: 503 ($[M+H]^+$), 253, 251. HR-CI-MS: 503.33780 ($[M+H]^+$, C₃₀H₄₇O₆'; calc. 503.3373).

2-Hexyl-5-hydroxy-7-methoxy-4H-1-benzopyran-4-one (11). Yellowish lacquer. UV (MeOH): 216, 244, 292 (sh), 321, 334; (MeOH + AlCl₃) 238, 345; (MeOH + AlCl₃ + HCl) 238, 345. ¹H-NMR $(400 \text{ MHz}, \text{CDCl}_3)$: 12.43 (s, HO-C(5)); 6.40 (d, J = 2.3, H-C(6)); 6.34 (d, J = 2.3, H-C(8)); 6.19 $(s, H-C(3))$; 3.83 $(s, MeO-C(7))$; 2.48 $(t, J = 7.7, CH₂(1'))$; 1.70 – 1.61, 1.39 – 1.31 $(2m, CH₂(2'))$ to $CH₂(5')$); 0.89 (t, J = 7.1, Me(6')). ¹³C-NMR (100 MHz, CDCl₃): 179.2 (C(4)); 166.3 (C(7)); 165.1 (C(5)); 157.2 (C(9)); 140.8 (C(2)); 114.5 (C(10)); 105.3 (C(3)); 99.5 (C(6/8)); 99.3 (C(8/6)); 55.4 (MeO-C(7)); 33.3 (C(1')); 31.1 (C(2')); 29.7 (C(3')); 27.7 (C(4')); 22.3 (C(5')); 13.9 (C(6')). FAB-MS (pos.): 277 ([M + H \rceil^+), 262. EI-MS (70 eV): 261 (97, $\lceil M - \text{Me} \rceil^+$), 218 (20, $\lceil M - 58 \rceil^+$), 205 (100, $\lceil M - 71 \rceil^+$), 177 (15, $[M-99]^+$). HR-ESI-MS: 299.12611 ($[M+Na]^+$, C₁₆H₂₀NaO[†]; calc. 299.12593).

5-Hydroxy-7-methoxy-2-pentyl-1H-quinolin-4-one (11a). For the preparation procedure, see Scheme and [30]. Colorless lacquer. ¹H-NMR (200 MHz, CDCl₃): 8.10 (br. s, H-N(1)); 6.29 (d, $J = 2.0$, $H-C(6)$; 6.15 (d, $J = 2.0$, $H-C(8)$; 5.98 (s, $H-C(3)$; 3.84 (s, $MeO-C(7)$); 2.57 (t, $J = 7.6$, CH₂(1')); 1.70 – 1.23 (m, CH₂(2') to CH₂(5')); 0.92 (t, J = 7.1, Me(6')). ¹³C-NMR (50 MHz, CDCl₃): 182.5 (C(4)); 164.3 (C(7)); 163.5 (C(5)); 153.0 (C(9)); 141.5 (C(2)); 107.7 (C(10)); 107.0 (C(3)); 96.6 (C(6/8)); 89.9 $(C(8/6))$; 55.5 (MeO-C(7)); 34.3 (C(1')); 31.1 (C(2')); 29.9 (C(3')); 27.9 (C(4')); 22.3 (C(5')); 13.8 $(C(6'))$. D/CI-MS: 262 $([M + H]^+)$.

REFERENCES

- [1] J. Hutchinson, 'The genera of flowering plants (Angiospermaceae), volume I, Dicotyledones', Clarendon Press, Oxford, 1964.
- [2] A. Cronquist, 'An integrated system of classification of flowering plants', Columbia University Press, New York, 1981.
- [3] W. S. Judd, S. R. Manchester, Brittonia 1997, 49, 384.
- [4] C. Bayer, M. F. Fay, A. Y. De Bruijn, V. Savolainen, C. M. Morton, K. Kubitzki, W. S. Alverson, M. W. Chase, Bot. J. Linn. Soc. 1999, 129, 267.
- [5] W. S. Alverson, B. A. Whitlock, R. Nyffeler, C. Bayer, D. A. Baum, Am. J. Bot. 1999, 86, 1474. [6] Angiosperm Phylogeny Group, 'An update of the Angiosperm Phylogeny Group classification for
- the orders and families of flowering plants: APGII', Bot. J. Linn. Soc. 2003, 141, 399.
- S. B. Mahato, A. P. Kundu, *Phytochemistry* 1994, 37, 1517.
- [8] M. Takasaki, T. Konoshima, H. Tokuda, K. Masuda, Y. Arai, K. Shiojima, H. Ageta, Biol. Pharm. Bull. 1999, 22, 606.
- [9] K. Shiojima, Y. Arai, K. Masuda, Y. Takase, T. Ageta, H. Ageta, Chem. Pharm. Bull. 1992, 40, 1683.
- [10] C. J. Pouchert, J. Behnke, 'The Aldrich Library of ¹³C- and ¹H-FT-NMR Spectra', Aldrich Chemical Company, Milwaukee, 1993.
- [11] L. A. Colett, M. T. Davies-Coleman, D. C. Gournelis, G. G. Laskaris, D. E. A. Rivett, R. Verpoorte, 'Progress in the chemistry of organic natural products', Springer-Verlag, Wien, 1998.
- [12] G. A. Cordell, 'Introduction to alkaloids, a biogenetic approach', John Wiley & Sons, New York, 1981.
- [13] G. J. Kapadia, Y. N. Shukla, J. F. Morton, H. A. Lloyd, *Phytochemistry* 1977, 16, 1431.
- [14] D. Eichinger, A. Bacher, M. H. Zenk, W. Eisenreich, Phytochemistry 1999, 51, 223.
- [15] S. Damtoft, S. Rosendal Jensen, B. J. Nielsen, Phytochemistry 1981, 20, 2717.
- [16] S. Rosendal Jensen, B. J. Nielsen, Biochem. Syst. Ecol. 1979, 7, 103.
- [17] H. Inouye, T. Nishioka, Chem. Pharm. Bull. 1973, 21, 497.
- [18] A. Kocsis, L. F. Szabó, B. Podányi, J. Nat. Prod. 1993, 9, 1486.
- [19] R. Hänsel, J.-T. Huang, Arch. Pharm. 1977, 310, 38.
- [20] H. J. Kim, E.-R. Woo, H. Park, J. Nat. Prod. 1994, 57, 581.
- [21] M. Arisawa, S. S. Handa, D. D. McPherson, D. C. Lankin, G. A. Cordell, H. H. S. Fong, N. R. Farnsworth, J. Nat. Prod. 1984, 47, 300.
- [22] V. U. Ahmad, F. Ullah, J. Hussain, U. Farooq, M. Zubair, M. T. H. Khan, M. I. Choudhary, Chem. Pharm. Bull. 2004, 52, 1458.
- [23] A. B. Ray, S. K. Chattopadhyay, S. Kumar, C. Konno, Y. Kiso, H. Hikino, Tetrahedron 1985, 41, 209.
- [24] E. Pretsch, T. Clerc, J. Seilb, W. Simon, 'Tables of spectral data for structure determination of organic compounds', 2nd edn., Springer-Verlag, Berlin, 1989.
- [25] K. Sakano, M. Ohshima, Agric. Biol. Chem. 1986, 50, 1239.
- [26] H. Nakagawa, Y. Takaishi, N. Tanaka, K. Tsuchiya, H. Shibata, T. Higuti, J. Nat. Prod. 2006, 69, 1177.
- [27] R. D. Bennett, S. Hasegawa, Z. Herman, Phytochemistry 1989, 28, 2777.
- [28] C. Jiménez, M. Marcos, M. C. Villarde, R. Riguera, L. Castedo, F. Stermitz, Phytochemistry 1989, 28, 1992.
- [29] M. F. das Graças Fernandes da Silva, M. S. Soares, J. B. Fernandes, P. C. Vieira, Alkaloids Chem. Biol. 2007, 64, 139.
- [30] M. Hadjeri, E.-L. Peiller, C. Beney, N. Deka, M. A. Lawson, C. Dumontet, A. Boumendjel, J. Med. Chem. 2004, 47, 4964.
- [31] M. I. Ybarra, C. A. N. Catalán, J. G. Díaz, W. Herz, Phytochemistry 1992, 31, 3627.
- [32] A. M. Galal, E. A. Abourashed, S. A. Ross, M. A. ElSohly, M. S. Al-Said, F. S. El-Feraly, J. Nat. Prod. 2001, 64, 399.
- [33] L.-Y. Wang, T. Unehara, S. Kitanaka, Chem. Pharm. Bull. 2005, 53, 137.
- [34] M.-A. Tanitsu, Y. Takaya, M. Akasaka, M. Niwa, Y. Oshima, Phytochemistry 2002, 59, 845.
- [35] H. Matsuda, T. Morikawa, I. Togushida, K. Ninomiya, M. Yoshikawa, Chem. Pharm. Bull. 2001, 49, 1558.
- [36] N. Takeuchi, T. Fujita, K. Goto, N. Morisaki, N. Osone, S. Tobinaga, Chem. Pharm. Bull. 1993, 41, 923.
- [37] F. Nagashima, S. Takaoka, S. Huneck, Y. Asakawa, Phytochemistry 1999, 51, 563.
- [38] Y. Kashman, S. Hirsch, *J. Nat. Prod.* **1991**, 54, 1430.
- [39] I. C. Moreira, J. H. G. Lago, N. F. Roque, Biochem. Syst. Ecol. 2005, 33, 948.
- [40] C. Kamperdick, N. M. Phuong, T. V. Sung, G. Adam, Phytochemistry 2001, 56, 335.
- [41] C. Kamperdick, N. M. Phuong, G. Adam, T. V. Sung, Phytochemistry 2003, 64, 811.
- [42] I. Muhammad, K. A. El Sayed, J. S. Mossa, M. S. Al-Said, F. S. El-Feraly, A. M. Clark, C. D. Hufford, S. Oh, A. M. S. Mayer, J. Nat. Prod. 2000, 63, 605.
- [43] S. Kosela, Y. Yulizar, T. M. Chairul, Y. Asaka, Phytochemistry 1995, 38, 691.
- [44] B. Ma, Y.-P. Shi, Z.-J. Jia, Planta Med. 1997, 63, 573.
- [45] R. R. T. Majinda, A. I. Gray, R. D. Waigh, P. G. Waterman, Phytochemistry 1995, 38, 461.
- [46] A. Emile, J. Waikedre, C. Herrenknecht, C. Fourneau, J.-C. Gantier, E. Hnawia, P. Cabalion, R. Hocquemiller, A. Fournet, Phytother. Res. 2007, 21, 398.

HELVETICA CHIMICA ACTA – Vol. 91 (2008) 1117

- [47] H. El-Seedi, M. H. Zahra, U. Goransson, R. Verpoorte, *Phytochem. Rev.* 2007, 6, 143.
- [48] P. G. Waterman, S. Mole, 'Analysis of Phenolic Plant Metabolites', Blackwell, Oxford, 1994.
- [49] K. Ghedira, R. Chemli, B. Richard, J.-M. Nuzillard, M. Zeches, L. Le Men-Olivier, Phytochemistry 1993, 32, 1591.

Received January 14, 2008